Type 2 diabetes: Difference between revisions

This is a good article. Click here for more information.
Page semi-protected
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎Epidemiology: better than seting px
Line 89: Line 89:
===Medications===
===Medications===
[[Image:Metformin 500mg Tablets.jpg|thumb|Metformin 500mg tablets.]]
[[Image:Metformin 500mg Tablets.jpg|thumb|Metformin 500mg tablets.]]
There are several classes of [[anti-diabetic medications]] available. [[Metformin]] is generally recommended as a first line treatment as there is some evidence that it decreases mortality;<ref name=AFP09/> however, this conclusion is questioned.<ref>{{cite journal|last=Boussageon|first=R|author2=Supper, I |author3=Bejan-Angoulvant, T |author4=Kellou, N |author5=Cucherat, M |author6=Boissel, JP |author7=Kassai, B |author8=Moreau, A |author9=Gueyffier, F |author10= Cornu, C |title=Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials|journal=PLoS medicine|year=2012|volume=9|issue=4|pages=e1001204|pmid=22509138|doi=10.1371/journal.pmed.1001204|pmc=3323508|editor1-last=Groop|editor1-first=Leif}}</ref> A second oral agent of another class may be used if metformin is not sufficient.<ref>{{cite journal|last=Qaseem|first=A|coauthors=Humphrey, LL, Sweet, DE, Starkey, M, Shekelle, P, Clinical Guidelines Committee of the American College of, Physicians|title=Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians|journal=Annals of internal medicine|date=2012-02-07|volume=156|issue=3|pages=218–31|pmid=22312141|doi=10.7326/0003-4819-156-3-201202070-00011}}</ref> Other classes of medications include: [[sulfonylureas]], [[nonsulfonylurea secretagogues]], [[alpha glucosidase inhibitors]], [[thiazolidinediones]], [[glucagon-like peptide-1 analog]], and [[dipeptidyl peptidase-4 inhibitor]]s.<ref name=AFP09/><ref>{{cite journal|title=Standards of medical care in diabetes--2012 |journal=Diabetes Care |volume=35 Suppl 1 |issue= Suppl 1|pages=S11–63 |date=January 2012 |pmid=22187469 |doi=10.2337/dc12-s011|publisher=American Diabetes Association |pmc= 3632172}}</ref> [[Rosiglitazone]], a thiazolidinedione, has not been found to improve long-term outcomes even though it improves blood sugar levels.<ref>{{cite journal|last=Richter|first=B|author2=Bandeira-Echtler, E |author3=Bergerhoff, K |author4=Clar, C |author5= Ebrahim, SH |title=Rosiglitazone for type 2 diabetes mellitus|journal=The Cochrane database of systematic reviews|date=18 July 2007|issue=3|pages=CD006063|pmid=17636824|doi=10.1002/14651858.CD006063.pub2|editor1-last=Richter|editor1-first=Bernd}}</ref> Additionally it is associated with increased rates of heart disease and death.<ref>{{cite journal|last=Chen|first=X|author2=Yang, L |author3=Zhai, SD |title=Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies|journal=Chinese medical journal|date=December 2012|volume=125|issue=23|pages=4301–6|pmid=23217404}}</ref> Metformin should not be used in those with severe kidney or liver problems.<ref name=Vij2010/> Injections of [[insulin]] may either be added to oral medication or used alone.<ref name=AFP09/>
There are several classes of [[anti-diabetic medications]] available. [[Metformin]] is generally recommended as a first line treatment as there is some evidence that it decreases mortality;<ref name=AFP09/> however, this conclusion is questioned.<ref>{{cite journal|last=Boussageon|first=R|author2=Supper, I |author3=Bejan-Angoulvant, T |author4=Kellou, N |author5=Cucherat, M |author6=Boissel, JP |author7=Kassai, B |author8=Moreau, A |author9=Gueyffier, F |author10= Cornu, C |title=Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials|journal=PLoS medicine|year=2012|volume=9|issue=4|pages=e1001204|pmid=22509138|doi=10.1371/journal.pmed.1001204|pmc=3323508|editor1-last=Groop|editor1-first=Leif}}</ref>
A second oral agent of another class or insulin may be added if metformin is not sufficient after three months.<ref name=ADA2015>{{cite journal|last1=Inzucchi|first1=SE|last2=Bergenstal|first2=RM|last3=Buse|first3=JB|last4=Diamant|first4=M|last5=Ferrannini|first5=E|last6=Nauck|first6=M|last7=Peters|first7=AL|last8=Tsapas|first8=A|last9=Wender|first9=R|last10=Matthews|first10=DR|title=Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.|journal=Diabetologia|date=March 2015|volume=58|issue=3|pages=429-42|pmid=25583541}}</ref> Other classes of medications include: [[sulfonylureas]], [[thiazolidinediones]], [[dipeptidyl peptidase-4 inhibitor]]s, [[SGLT2 inhibitors]], and [[glucagon-like peptide-1 analog]].<ref name=ADA2015/> There is no significant difference between these agents.<ref name=ADA2015/> [[Rosiglitazone]], a thiazolidinedione, has not been found to improve long-term outcomes even though it improves blood sugar levels.<ref>{{cite journal|last=Richter|first=B|author2=Bandeira-Echtler, E |author3=Bergerhoff, K |author4=Clar, C |author5= Ebrahim, SH |title=Rosiglitazone for type 2 diabetes mellitus|journal=The Cochrane database of systematic reviews|date=18 July 2007|issue=3|pages=CD006063|pmid=17636824|doi=10.1002/14651858.CD006063.pub2|editor1-last=Richter|editor1-first=Bernd}}</ref> Additionally it is associated with increased rates of heart disease and death.<ref>{{cite journal|last=Chen|first=X|author2=Yang, L |author3=Zhai, SD |title=Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies|journal=Chinese medical journal|date=December 2012|volume=125|issue=23|pages=4301–6|pmid=23217404}}</ref> Metformin should not be used in those with severe kidney or liver problems.<ref name=Vij2010/> Injections of [[insulin]] may either be added to oral medication or used alone.<ref name=AFP09/>


Most people do not initially need [[insulin]].<ref name=Green2011/> When it is used, a long-acting formulation is typically added at night, with oral medications being continued.<ref name=Vij2010/><ref name=AFP09/> Doses are then increased to effect (blood sugar levels being well controlled).<ref name=AFP09/> When nightly insulin is insufficient, twice daily insulin may achieve better control.<ref name=Vij2010/> The long acting insulins [[insulin glargine|glargine]] and [[insulin detemir|detemir]] are equally safe and effective,<ref>{{Cite journal | last1 = Swinnen | first1 = SG. | last2 = Simon | first2 = AC. | last3 = Holleman | first3 = F. | last4 = Hoekstra | first4 = JB. | last5 = Devries | first5 = JH. | title = Insulin detemir versus insulin glargine for type 2 diabetes mellitus | journal = Cochrane Database Syst Rev | volume = | issue = 7 | pages = CD006383 | year = 2011 | doi = 10.1002/14651858.CD006383.pub2 | pmid = 21735405 | editor1-last = Simon | editor1-first = Airin CR }}</ref> and do not appear much better than neutral protamine Hagedorn [[NPH insulin|(NPH) insulin]], but as they are significantly more expensive, they are not cost effective as of 2010.<ref>{{cite journal|last=Waugh|first=N|author2=Cummins, E|author3=Royle, P|author4=Clar, C|author5=Marien, M|author6=Richter, B|author7=Philip, S|title=Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation|journal=Health technology assessment (Winchester, England)|date=July 2010|volume=14|issue=36|pages=1–248|pmid=20646668|doi=10.3310/hta14360}}</ref> In those who are [[pregnant]] insulin is generally the treatment of choice.<ref name=Vij2010/> [[Angiotensin-converting enzyme inhibitors]] (ACEIs) prevent [[kidney disease]] and improve outcomes in those with diabetes.<ref>{{cite journal|last=Lv|first=J|author2=Perkovic, V |author3=Foote, CV |author4=Craig, ME |author5=Craig, JC |author6= Strippoli, GF |title=Antihypertensive agents for preventing diabetic kidney disease|journal=The Cochrane database of systematic reviews|date=12 December 2012|volume=12|pages=CD004136|pmid=23235603|doi=10.1002/14651858.CD004136.pub3|editor1-last=Strippoli|editor1-first=Giovanni FM}}</ref><ref name=Cheng2014>{{cite journal|last1=Cheng|first1=J|last2=Zhang|first2=W|last3=Zhang|first3=X|last4=Han|first4=F|last5=Li|first5=X|last6=He|first6=X|last7=Li|first7=Q|last8=Chen|first8=J|title=Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.|journal=JAMA internal medicine|date=May 2014|volume=174|issue=5|pages=773–85|pmid=24687000|doi=10.1001/jamainternmed.2014.348}}</ref> The similar medications [[angiotensin receptor blockers]] (ARBs) do not.<ref name=Cheng2014/>
Most people do not initially need [[insulin]].<ref name=Green2011/> When it is used, a long-acting formulation is typically added at night, with oral medications being continued.<ref name=Vij2010/><ref name=AFP09/> Doses are then increased to effect (blood sugar levels being well controlled).<ref name=AFP09/> When nightly insulin is insufficient, twice daily insulin may achieve better control.<ref name=Vij2010/> The long acting insulins [[insulin glargine|glargine]] and [[insulin detemir|detemir]] are equally safe and effective,<ref>{{Cite journal | last1 = Swinnen | first1 = SG. | last2 = Simon | first2 = AC. | last3 = Holleman | first3 = F. | last4 = Hoekstra | first4 = JB. | last5 = Devries | first5 = JH. | title = Insulin detemir versus insulin glargine for type 2 diabetes mellitus | journal = Cochrane Database Syst Rev | volume = | issue = 7 | pages = CD006383 | year = 2011 | doi = 10.1002/14651858.CD006383.pub2 | pmid = 21735405 | editor1-last = Simon | editor1-first = Airin CR }}</ref> and do not appear much better than neutral protamine Hagedorn [[NPH insulin|(NPH) insulin]], but as they are significantly more expensive, they are not cost effective as of 2010.<ref>{{cite journal|last=Waugh|first=N|author2=Cummins, E|author3=Royle, P|author4=Clar, C|author5=Marien, M|author6=Richter, B|author7=Philip, S|title=Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation|journal=Health technology assessment (Winchester, England)|date=July 2010|volume=14|issue=36|pages=1–248|pmid=20646668|doi=10.3310/hta14360}}</ref> In those who are [[pregnant]] insulin is generally the treatment of choice.<ref name=Vij2010/> [[Angiotensin-converting enzyme inhibitors]] (ACEIs) prevent [[kidney disease]] and improve outcomes in those with diabetes.<ref>{{cite journal|last=Lv|first=J|author2=Perkovic, V |author3=Foote, CV |author4=Craig, ME |author5=Craig, JC |author6= Strippoli, GF |title=Antihypertensive agents for preventing diabetic kidney disease|journal=The Cochrane database of systematic reviews|date=12 December 2012|volume=12|pages=CD004136|pmid=23235603|doi=10.1002/14651858.CD004136.pub3|editor1-last=Strippoli|editor1-first=Giovanni FM}}</ref><ref name=Cheng2014>{{cite journal|last1=Cheng|first1=J|last2=Zhang|first2=W|last3=Zhang|first3=X|last4=Han|first4=F|last5=Li|first5=X|last6=He|first6=X|last7=Li|first7=Q|last8=Chen|first8=J|title=Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.|journal=JAMA internal medicine|date=May 2014|volume=174|issue=5|pages=773–85|pmid=24687000|doi=10.1001/jamainternmed.2014.348}}</ref> The similar medications [[angiotensin receptor blockers]] (ARBs) do not.<ref name=Cheng2014/>

Revision as of 05:20, 13 March 2015

Type 2 diabetes
SpecialtyEndocrinology

Diabetes mellitus type 2 (formerly noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterized by hyperglycemia (high blood sugar) in the context of insulin resistance and relative lack of insulin.[2] This is in contrast to diabetes mellitus type 1, in which there is an absolute lack of insulin due to breakdown of islet cells in the pancreas.[3] The classic symptoms are excess thirst, frequent urination, and constant hunger. Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10% due primarily to diabetes mellitus type 1 and gestational diabetes. Obesity is thought to be the primary cause of type 2 diabetes in people who are genetically predisposed to the disease (although this is not the case in people of East-Asian ancestry).

Type 2 diabetes is initially managed by increasing exercise and dietary changes. If blood sugar levels are not adequately lowered by these measures, medications such as metformin or insulin may be needed. In those on insulin, there is typically the requirement to routinely check blood sugar levels.

Rates of type 2 diabetes have increased markedly since 1960 in parallel with obesity. As of 2010 there were approximately 285 million people diagnosed with the disease compared to around 30 million in 1985.[4][5] Long-term complications from high blood sugar can include heart disease, strokes, diabetic retinopathy where eyesight is affected, kidney failure which may require dialysis, and poor blood flow in the limbs leading to amputations. The acute complication of ketoacidosis, a feature of type 1 diabetes, is uncommon,[6] however hyperosmolar hyperglycemic state may occur.

Signs and symptoms

Overview of the most significant symptoms of diabetes.

The classic symptoms of diabetes are polyuria (frequent urination), polydipsia (increased thirst), polyphagia (increased hunger), and weight loss.[7] Other symptoms that are commonly present at diagnosis include a history of blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue.[3] Many people, however, have no symptoms during the first few years and are diagnosed on routine testing.[3] People with type 2 diabetes mellitus may rarely present with hyperosmolar hyperglycemic state (a condition of very high blood sugar associated with a decreased level of consciousness and low blood pressure).[3]

Complications

Main article: Complications of diabetes mellitus

Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.[4] This is partly due to a number of complications with which it is associated, including: two to four times the risk of cardiovascular disease, including ischemic heart disease and stroke; a 20-fold increase in lower limb amputations, and increased rates of hospitalizations.[4] In the developed world, and increasingly elsewhere, type 2 diabetes is the largest cause of nontraumatic blindness and kidney failure.[8] It has also been associated with an increased risk of cognitive dysfunction and dementia through disease processes such as Alzheimer's disease and vascular dementia.[9] Other complications include acanthosis nigricans, sexual dysfunction, and frequent infections.[7]

Cause

The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors.[8][10] While some of these factors are under personal control, such as diet and obesity, other factors are not, such as increasing age, female gender, and genetics.[4] A lack of sleep has been linked to type 2 diabetes.[11] This is believed to act through its effect on metabolism.[11] The nutritional status of a mother during fetal development may also play a role, with one proposed mechanism being that of altered DNA methylation.[12]

Lifestyle

Main article: Lifestyle causes of diabetes mellitus type 2

A number of lifestyle factors are known to be important to the development of type 2 diabetes, including obesity and overweight (defined by a body mass index of greater than 25), lack of physical activity, poor diet, stress, and urbanization.[4][13] Excess body fat is associated with 30% of cases in those of Chinese and Japanese descent, 60-80% of cases in those of European and African descent, and 100% of cases in Pima Indians and Pacific Islanders.[3] Those who are not obese often have a high waist–hip ratio.[3]

Dietary factors also influence the risk of developing type 2 diabetes. Consumption of sugar-sweetened drinks in excess is associated with an increased risk.[14][15] The type of fats in the diet are also important, with saturated fats and trans fatty acids increasing the risk, and polyunsaturated and monounsaturated fat decreasing the risk.[10] Eating lots of white rice appears to also play a role in increasing risk.[16] A lack of exercise is believed to cause 7% of cases.[17] Persistent organic pollutants may also play a role.[18]

Genetics

Main article: Genetic causes of diabetes mellitus type 2

Most cases of diabetes involve many genes, with each being a small contributor to an increased probability of becoming a type 2 diabetic.[4] If one identical twin has diabetes, the chance of the other developing diabetes within his lifetime is greater than 90%, while the rate for nonidentical siblings is 25–50%.[3] As of 2011, more than 36 genes had been found that contribute to the risk of type 2 diabetes.[19] All of these genes together still only account for 10% of the total heritable component of the disease.[19] The TCF7L2 allele, for example, increases the risk of developing diabetes by 1.5 times and is the greatest risk of the common genetic variants.[3] Most of the genes linked to diabetes are involved in beta cell functions.[3]

There are a number of rare cases of diabetes that arise due to an abnormality in a single gene (known as monogenic forms of diabetes or "other specific types of diabetes").[3][4] These include maturity onset diabetes of the young (MODY), Donohue syndrome, and Rabson-Mendenhall syndrome, among others.[4] Maturity onset diabetes of the young constitute 1–5% of all cases of diabetes in young people.[20]

Medical conditions

There are a number of medications and other health problems that can predispose to diabetes.[21] Some of the medications include: glucocorticoids, thiazides, beta blockers, atypical antipsychotics,[22] and statins.[23] Those who have previously had gestational diabetes are at a higher risk of developing type 2 diabetes.[7] Other health problems that are associated include: acromegaly, Cushing's syndrome, hyperthyroidism, pheochromocytoma, and certain cancers such as glucagonomas.[21] Testosterone deficiency is also associated with type 2 diabetes.[24][25]

Pathophysiology

Type 2 diabetes is due to insufficient insulin production from beta cells in the setting of insulin resistance.[3] Insulin resistance, which is the inability of cells to respond adequately to normal levels of insulin, occurs primarily within the muscles, liver, and fat tissue.[26] In the liver, insulin normally suppresses glucose release. However, in the setting of insulin resistance, the liver inappropriately releases glucose into the blood.[4] The proportion of insulin resistance versus beta cell dysfunction differs among individuals, with some having primarily insulin resistance and only a minor defect in insulin secretion and others with slight insulin resistance and primarily a lack of insulin secretion.[3]

Other potentially important mechanisms associated with type 2 diabetes and insulin resistance include: increased breakdown of lipids within fat cells, resistance to and lack of incretin, high glucagon levels in the blood, increased retention of salt and water by the kidneys, and inappropriate regulation of metabolism by the central nervous system.[4] However, not all people with insulin resistance develop diabetes, since an impairment of insulin secretion by pancreatic beta cells is also required.[3]

Diagnosis

WHO diabetes diagnostic criteria[27][28]  edit
Condition 2-hour glucose Fasting glucose HbA1c
Unit mmol/L mg/dL mmol/L mg/dL mmol/mol DCCT %
Normal < 7.8 < 140 < 6.1 < 110 < 42 < 6.0
Impaired fasting glycaemia < 7.8 < 140 6.1–7.0 110–125 42–46 6.0–6.4
Impaired glucose tolerance ≥ 7.8 ≥ 140 < 7.0 < 126 42–46 6.0–6.4
Diabetes mellitus ≥ 11.1 ≥ 200 ≥ 7.0 ≥ 126 ≥ 48 ≥ 6.5

The World Health Organization definition of diabetes (both type 1 and type 2) is for a single raised glucose reading with symptoms, otherwise raised values on two occasions, of either:[29]

  • fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl)
or

A random blood sugar of greater than 11.1 mmol/l (200 mg/dL) in association with typical symptoms[7] or a glycated hemoglobin (HbA1c) of greater than ≥ 48 mmol/mol (≥ 6.5 DCCT %) is another method of diagnosing diabetes.[4] In 2009 an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a threshold of ≥ 48 mmol/mol (≥ 6.5 DCCT %) should be used to diagnose diabetes.[30] This recommendation was adopted by the American Diabetes Association in 2010.[31] Positive tests should be repeated unless the person presents with typical symptoms and blood sugars >11.1 mmol/l (>200 mg/dl).[30]

Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or HbA1c and complications such as retinal problems.[4] A fasting or random blood sugar is preferred over the glucose tolerance test, as they are more convenient for people.[4] HbA1c has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose.[32] It is estimated that 20% of people with diabetes in the United States do not realize that they have the disease.[4]

Diabetes mellitus type 2 is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.[2] This is in contrast to diabetes mellitus type 1 in which there is an absolute insulin deficiency due to destruction of [islet cells in the pancreas and gestational diabetes mellitus that is a new onset of high blood sugars associated with pregnancy.[3] Type 1 and type 2 diabetes can typically be distinguished based on the presenting circumstances.[30] If the diagnosis is in doubt antibody testing may be useful to confirm type 1 diabetes and C-peptide levels may be useful to confirm type 2 diabetes,[33] with C-peptide levels normal or high in type 2 diabetes, but low in type 1 diabetes.

Screening

No major organization recommends universal screening for diabetes as there is no evidence that such a program would improve outcomes.[34] Screening is recommended by the United States Preventive Services Task Force (USPSTF) in adults without symptoms whose blood pressure is greater than 135/80 mmHg.[35] For those whose blood pressure is less, the evidence is insufficient to recommend for or against screening.[35]

The World Health Organization recommends testing those groups at high risk[34] and in 2014 the USPSTF is considering a similar recommendation.[36] High-risk groups in the United States include: those over 45 years old; those with a first degree relative with diabetes; some ethnic groups, including Hispanics, African-Americans, and Native-Americans; a history of gestational diabetes; polycystic ovary syndrome; excess weight; and conditions associated with metabolic syndrome.[7] The American Diabetes Association recommends screening those who have a BMI over 25 (in people of Asian descent screening is recommending for a BMI over 23.[37]

Prevention

Main article: Prevention of diabetes mellitus type 2

Onset of type 2 diabetes can be delayed or prevented through proper nutrition and regular exercise.[38][39] Intensive lifestyle measures may reduce the risk by over half.[8][40] The benefit of exercise occurs regardless of the person's initial weight or subsequent weight loss.[41] Evidence for the benefit of dietary changes alone, however, is limited,[42] with some evidence for a diet high in green leafy vegetables[43] and some for limiting the intake of sugary drinks.[14] In those with impaired glucose tolerance, diet and exercise either alone or in combination with metformin or acarbose may decrease the risk of developing diabetes.[8][44] Lifestyle interventions are more effective than metformin.[8] While low vitamin D levels are associated with an increased risk of diabetes, correcting the levels by supplementing vitamin D3 does not improve that risk.[45]

Management

Further information: Diabetes management

Management of type 2 diabetes focuses on lifestyle interventions, lowering other cardiovascular risk factors, and maintaining blood glucose levels in the normal range.[8] Self-monitoring of blood glucose for people with newly diagnosed type 2 diabetes was recommended by the British National Health Service in 2008,[46] however the benefit of self monitoring in those not using multi-dose insulin is questionable.[8][47] Managing other cardiovascular risk factors, such as hypertension, high cholesterol, and microalbuminuria, improves a person's life expectancy.[8] Decreasing the systolic blood pressure to less than 140 mmHg is associated with a lower risk of death and better outcomes.[48] Intensive blood pressure management (less than 130/80 mmHg) as opposed to standard blood pressure management (less than 140/85–100 mmHg) results in a slight decrease in stroke risk but no effect on overall risk of death.[49]

Intensive blood sugar lowering (HbA1c<6%) as opposed to standard blood sugar lowering (HbA1c of 7–7.9%) does not appear to change mortality.[50][51] The goal of treatment is typically an HbA1c of less than 7% or a fasting glucose of less than 6.7 mmol/L (120 mg/dL); however these goals may be changed after professional clinical consultation, taking into account particular risks of hypoglycemia and life expectancy.[7] It is recommended that all people with type 2 diabetes get regular ophthalmology examination.[3] Treating gum disease in those with diabetes may result in a small improvement in blood sugar levels.[52]

Lifestyle

A proper diet and exercise are the foundations of diabetic care,[7] with a greater amount of exercise yielding better results.[53] Aerobic exercise leads to a decrease in HbA1c and improved insulin sensitivity.[53] Resistance training is also useful and the combination of both types of exercise may be most effective.[53] A diabetic diet that promotes weight loss is important.[54] While the best diet type to achieve this is controversial,[54] a low glycemic index diet has been found to improve blood sugar control.[55] Culturally appropriate education may help people with type 2 diabetes control their blood sugar levels, for up to six months at least.[56] If changes in lifestyle in those with mild diabetes has not resulted in improved blood sugars within six weeks, medications should then be considered.[7] There is not enough evidence to determine if lifestyle interventions affect mortality in those who already have DM.[57]

Medications

Metformin 500mg tablets.

There are several classes of anti-diabetic medications available. Metformin is generally recommended as a first line treatment as there is some evidence that it decreases mortality;[8] however, this conclusion is questioned.[58]

A second oral agent of another class or insulin may be added if metformin is not sufficient after three months.[59] Other classes of medications include: sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors, and glucagon-like peptide-1 analog.[59] There is no significant difference between these agents.[59] Rosiglitazone, a thiazolidinedione, has not been found to improve long-term outcomes even though it improves blood sugar levels.[60] Additionally it is associated with increased rates of heart disease and death.[61] Metformin should not be used in those with severe kidney or liver problems.[7] Injections of insulin may either be added to oral medication or used alone.[8]

Most people do not initially need insulin.[3] When it is used, a long-acting formulation is typically added at night, with oral medications being continued.[7][8] Doses are then increased to effect (blood sugar levels being well controlled).[8] When nightly insulin is insufficient, twice daily insulin may achieve better control.[7] The long acting insulins glargine and detemir are equally safe and effective,[62] and do not appear much better than neutral protamine Hagedorn (NPH) insulin, but as they are significantly more expensive, they are not cost effective as of 2010.[63] In those who are pregnant insulin is generally the treatment of choice.[7] Angiotensin-converting enzyme inhibitors (ACEIs) prevent kidney disease and improve outcomes in those with diabetes.[64][65] The similar medications angiotensin receptor blockers (ARBs) do not.[65]

Surgery

Weight loss surgery in those who are obese is an effective measure to treat diabetes.[66] Many are able to maintain normal blood sugar levels with little or no medications following surgery[67] and long-term mortality is decreased.[68] There however is some short-term mortality risk of less than 1% from the surgery.[69] The body mass index cutoffs for when surgery is appropriate are not yet clear.[68] It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.[70]

Epidemiology

Prevalence of diabetes worldwide in 2000 (per 1000 inhabitants). World average was 2.8%. Template:Multicol
  no data
  ≤ 7.5
  7.5–15
  15–22.5
  22.5–30
  30–37.5
  37.5–45
Template:Multicol-break
  45–52.5
  52.5–60
  60–67.5
  67.5–75
  75–82.5
  ≥ 82.5
Template:Multicol-end

Globally as of 2010 it was estimated that there were 285 million people with type 2 diabetes making up about 90% of diabetes cases.[4] This is equivalent to about 6% of the world's adult population.[71] Diabetes is common both in the developed and the developing world.[4] It remains uncommon, however, in the underdeveloped world.[3]

Women seem to be at a greater risk as do certain ethnic groups,[4][72] such as South Asians, Pacific Islanders, Latinos, and Native Americans.[7] This may be due to enhanced sensitivity to a Western lifestyle in certain ethnic groups.[73] Traditionally considered a disease of adults, type 2 diabetes is increasingly diagnosed in children in parallel with rising obesity rates.[4] Type 2 diabetes is now diagnosed as frequently as type 1 diabetes in teenagers in the United States.[3]

Rates of diabetes in 1985 were estimated at 30 million, increasing to 135 million in 1995 and 217 million in 2005.[5] This increase is believed to be primarily due to the global population aging, a decrease in exercise, and increasing rates of obesity.[5] The five countries with the greatest number of people with diabetes as of 2000 are India having 31.7 million, China 20.8 million, the United States 17.7 million, Indonesia 8.4 million, and Japan 6.8 million.[74] It is recognized as a global epidemic by the World Health Organization.[75]

History

Main article: History of diabetes

Diabetes is one of the first diseases described[76] with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine."[77] The first described cases are believed to be of type 1 diabetes.[77] Indian physicians around the same time identified the disease and classified it as madhumeha or honey urine noting that the urine would attract ants.[77] The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Appollonius Of Memphis.[77] The disease was rare during the time of the Roman empire with Galen commenting that he had only seen two cases during his career.[77]

Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400-500 AD with type 1 associated with youth and type 2 with being overweight.[77] The term "mellitus" or "from honey" was added by the Briton John Rolle in the late 1700s to separate the condition from diabetes insipidus which is also associated with frequent urination.[77] Effective treatment was not developed until the early part of the 20th century when the Canadians Frederick Banting and Charles Best discovered insulin in 1921 and 1922.[77] This was followed by the development of the long acting NPH insulin in the 1940s.[77]

References

  1. ^ "Diabetes Blue Circle Symbol". International Diabetes Federation. 17 March 2006.
  2. ^ a b Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Cotran, Ramzi S. ; Robbins, Stanley L. (2005). Robbins and Cotran Pathologic Basis of Disease (7th ed.). Philadelphia, Pa.: Saunders. pp. 1194–1195. ISBN 0-7216-0187-1.{{cite book}}: CS1 maint: multiple names: authors list (link)
  3. ^ a b c d e f g h i j k l m n o p q r Shoback, edited by David G. Gardner, Dolores (2011). Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. pp. Chapter 17. ISBN 0-07-162243-8. {{cite book}}: |first= has generic name (help)CS1 maint: multiple names: authors list (link)
  4. ^ a b c d e f g h i j k l m n o p q r Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371–1435. ISBN 978-1-4377-0324-5.
  5. ^ a b c Smyth, S; Heron, A (January 2006). "Diabetes and obesity: the twin epidemics". Nature Medicine. 12 (1): 75–80. doi:10.1038/nm0106-75. PMID 16397575.
  6. ^ Fasanmade, OA; Odeniyi, IA; Ogbera, AO (June 2008). "Diabetic ketoacidosis: diagnosis and management". African journal of medicine and medical sciences. 37 (2): 99–105. PMID 18939392.
  7. ^ a b c d e f g h i j k l m Vijan, S (2010-03-02). "Type 2 diabetes". Annals of internal medicine. 152 (5): ITC31–15, quiz ITC316. doi:10.1059/0003-4819-152-5-201003020-01003. PMID 20194231.
  8. ^ a b c d e f g h i j k l Ripsin CM, Kang H, Urban RJ (January 2009). "Management of blood glucose in type 2 diabetes mellitus". Am Fam Physician. 79 (1): 29–36. PMID 19145963.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Pasquier, F (October 2010). "Diabetes and cognitive impairment: how to evaluate the cognitive status?". Diabetes & metabolism. 36 Suppl 3: S100–5. doi:10.1016/S1262-3636(10)70475-4. PMID 21211730.
  10. ^ a b Risérus U, Willett WC, Hu FB (January 2009). "Dietary fats and prevention of type 2 diabetes". Progress in Lipid Research. 48 (1): 44–51. doi:10.1016/j.plipres.2008.10.002. PMC 2654180. PMID 19032965.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ a b Touma, C; Pannain, S (August 2011). "Does lack of sleep cause diabetes?". Cleveland Clinic journal of medicine. 78 (8): 549–58. doi:10.3949/ccjm.78a.10165. PMID 21807927.
  12. ^ Christian, P; Stewart, CP (March 2010). "Maternal micronutrient deficiency, fetal development, and the risk of chronic disease". The Journal of nutrition. 140 (3): 437–45. doi:10.3945/jn.109.116327. PMID 20071652.
  13. ^ Abdullah, A; Peeters, A; de Courten, M; Stoelwinder, J (September 2010). "The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies". Diabetes research and clinical practice. 89 (3): 309–19. doi:10.1016/j.diabres.2010.04.012. PMID 20493574.
  14. ^ a b Malik, VS (2010-03-23). "Sugar Sweetened Beverages, Obesity, Type 2 Diabetes and Cardiovascular Disease risk". Circulation. 121 (11): 1356–64. doi:10.1161/CIRCULATIONAHA.109.876185. PMC 2862465. PMID 20308626. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help) Cite error: The named reference "SSB2010" was defined multiple times with different content (see the help page).
  15. ^ Malik, VS (November 2010). "Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes: A meta-analysis". Diabetes Care. 33 (11): 2477–83. doi:10.2337/dc10-1079. PMC 2963518. PMID 20693348. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  16. ^ Hu, EA; Pan, A; Malik, V; Sun, Q (2012-03-15). "White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review". BMJ (Clinical research ed.). 344: e1454. doi:10.1136/bmj.e1454. PMC 3307808. PMID 22422870.
  17. ^ Lee, I-Min; Shiroma, Eric J; Lobelo, Felipe; Puska, Pekka; Blair, Steven N; Katzmarzyk, Peter T (1 July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". The Lancet. 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMC 3645500. PMID 22818936.
  18. ^ Lind, L; Lind, PM (Jun 2012). "Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease?". Journal of internal medicine. 271 (6): 537–53. doi:10.1111/j.1365-2796.2012.02536.x. PMID 22372998.
  19. ^ a b Herder, C; Roden, M (June 2011). "Genetics of type 2 diabetes: pathophysiologic and clinical relevance". European journal of clinical investigation. 41 (6): 679–92. doi:10.1111/j.1365-2362.2010.02454.x. PMID 21198561.
  20. ^ "Monogenic Forms of Diabetes: Neonatal Diabetes Mellitus and Maturity-onset Diabetes of the Young". National Diabetes Information Clearinghouse (NDIC). National Institute of Diabetes and Digestive and Kidney Diseases, NIH. March 2007. Retrieved 2008-08-04.
  21. ^ a b Bethel, edited by Mark N. Feinglos, M. Angelyn (2008). Type 2 diabetes mellitus: an evidence-based approach to practical management. Totowa, NJ: Humana Press. p. 462. ISBN 978-1-58829-794-5. {{cite book}}: |first= has generic name (help)CS1 maint: multiple names: authors list (link)
  22. ^ Izzedine, H; Launay-Vacher, V; Deybach, C; Bourry, E; Barrou, B; Deray, G (November 2005). "Drug-induced diabetes mellitus". Expert opinion on drug safety. 4 (6): 1097–109. doi:10.1517/14740338.4.6.1097. PMID 16255667.
  23. ^ Sampson, UK (July 2011). "Are statins diabetogenic?". Current Opinion in Cardiology. 26 (4): 342–7. doi:10.1097/HCO.0b013e3283470359. PMC 3341610. PMID 21499090. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  24. ^ Saad F, Gooren L (March 2009). "The role of testosterone in the metabolic syndrome: a review". The Journal of Steroid Biochemistry and Molecular Biology. 114 (1–2): 40–3. doi:10.1016/j.jsbmb.2008.12.022. PMID 19444934.
  25. ^ Farrell JB, Deshmukh A, Baghaie AA (2008). "Low testosterone and the association with type 2 diabetes". The Diabetes Educator. 34 (5): 799–806. doi:10.1177/0145721708323100. PMID 18832284.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  26. ^ Diabetes mellitus a guide to patient care. Philadelphia: Lippincott Williams & Wilkins. 2007. p. 15. ISBN 978-1-58255-732-8.
  27. ^ Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation (PDF). Geneva: World Health Organization. 2006. p. 21. ISBN 978-92-4-159493-6.
  28. ^ Vijan S (March 2010). "In the clinic. Type 2 diabetes". Annals of Internal Medicine. 152 (5): ITC31-15, quiz ITC316. doi:10.7326/0003-4819-152-5-201003020-01003. PMID 20194231.
  29. ^ World Health Organization. "Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus". Retrieved 2007-05-29.
  30. ^ a b c International Expert, Committee (July 2009). "International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes". Diabetes Care. 32 (7): 1327–34. doi:10.2337/dc09-9033. PMC 2699715. PMID 19502545.
  31. ^ "Diagnosis and classification of diabetes mellitus". Diabetes Care. 33 Suppl 1 (Supplement_1). American Diabetes Association: S62–9. January 2010. doi:10.2337/dc10-S062. PMC 2797383. PMID 20042775.
  32. ^ "Diagnosis and classification of diabetes mellitus". Diabetes Care. 35 Suppl 1 (Suppl 1). American Diabetes Association: S64–71. January 2012. doi:10.2337/dc12-s064. PMC 3632174. PMID 22187472.
  33. ^ Diabetes mellitus a guide to patient care. Philadelphia: Lippincott Williams & Wilkins. 2007. p. 201. ISBN 978-1-58255-732-8.
  34. ^ a b Valdez R (2009). "Detecting Undiagnosed Type 2 Diabetes: Family History as a Risk Factor and Screening Tool". J Diabetes Sci Technol. 3 (4): 722–6. doi:10.1177/193229680900300417. PMC 2769984. PMID 20144319.
  35. ^ a b "Screening: Type 2 Diabetes Mellitus in Adults". U.S. Preventive Services Task Force. 2008. Retrieved 2014-03-16.
  36. ^ "Draft Recommendation Statement Screening for Abnormal Glucose and Type 2 Diabetes Mellitus". http://www.uspreventiveservicestaskforce.org/. Retrieved 7 October 2014. {{cite web}}: External link in |website= (help)
  37. ^ "Standards of Medical Care in Diabetes--2015: Summary of Revisions". Diabetes Care. 54 (38). 2015. doi:10.2337/dc15-S003.
  38. ^ Raina Elley C, Kenealy T (December 2008). "Lifestyle interventions reduced the long-term risk of diabetes in adults with impaired glucose tolerance". Evid Based Med. 13 (6): 173. doi:10.1136/ebm.13.6.173. PMID 19043031.
  39. ^ Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roqué I Figuls M, Richter B, Mauricio D (2008). Mauricio, Didac (ed.). "Exercise or exercise and diet for preventing type 2 diabetes mellitus". Cochrane Database Syst Rev (3): CD003054. doi:10.1002/14651858.CD003054.pub3. PMID 18646086.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  40. ^ Schellenberg, ES.; Dryden, DM.; Vandermeer, B.; Ha, C.; Korownyk, C. (October 2013). "Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes: A Systematic Review and Meta-analysis". Ann Intern Med. 159 (8): 543–51. doi:10.7326/0003-4819-159-8-201310150-00007. PMID 24126648.
  41. ^ O'Gorman, DJ; Krook, A (September 2011). "Exercise and the treatment of diabetes and obesity". The Medical clinics of North America. 95 (5): 953–69. doi:10.1016/j.mcna.2011.06.007. PMID 21855702.
  42. ^ Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H (2008). Nield, Lucie (ed.). "Dietary advice for the prevention of type 2 diabetes mellitus in adults". Cochrane Database Syst Rev (3): CD005102. doi:10.1002/14651858.CD005102.pub2. PMID 18646120.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  43. ^ Carter, P (2010-08-18). "Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis". BMJ (Clinical research ed.). 341: c4229. doi:10.1136/bmj.c4229. PMC 2924474. PMID 20724400. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  44. ^ Santaguida PL, Balion C, Hunt D; et al. (August 2005). "Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose" (PDF). Evid Rep Technol Assess (Summ) (128): 1–11. PMID 16194123. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  45. ^ Seida, Jennifer C.; Mitri, Joanna; Colmers, Isabelle N.; Majumdar, Sumit R.; Davidson, Mayer B.; Edwards, Alun L.; Hanley, David A.; Pittas, Anastassios G.; Tjosvold, Lisa; Johnson, Jeffrey A. (Oct 2014). "Effect of Vitamin D3 Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis". The Journal of Clinical Endocrinology & Metabolism. 99 (10): 3551–3560. doi:10.1210/jc.2014-2136. PMID 25062463.
  46. ^ "Clinical Guideline:The management of type 2 diabetes (update)".
  47. ^ Farmer, AJ (27 February 2012). "Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes". BMJ (Clinical research ed.). 344: e486. doi:10.1136/bmj.e486. PMID 22371867. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  48. ^ Emdin, CA; Rahimi, K; Neal, B; Callender, T; Perkovic, V; Patel, A (10 February 2015). "Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis". JAMA. 313 (6): 603–15. PMID 25668264.
  49. ^ McBrien, K; Rabi, DM; Campbell, N; Barnieh, L; Clement, F; Hemmelgarn, BR; Tonelli, M; Leiter, LA; Klarenbach, SW; Manns, BJ (6 August 2012). "Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis". Archives of Internal Medicine. 172 (17): 1–8. doi:10.1001/archinternmed.2012.3147. PMID 22868819.
  50. ^ Boussageon, R; Bejan-Angoulvant, T; Saadatian-Elahi, M; Lafont, S; Bergeonneau, C; Kassaï, B; Erpeldinger, S; Wright, JM; Gueyffier, F; Cornu, C (2011-07-26). "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials". BMJ (Clinical research ed.). 343: d4169. doi:10.1136/bmj.d4169. PMC 3144314. PMID 21791495.
  51. ^ Webster, MW (July 2011). "Clinical practice and implications of recent diabetes trials". Current Opinion in Cardiology. 26 (4): 288–93. doi:10.1097/HCO.0b013e328347b139. PMID 21577100.
  52. ^ Simpson, TC.; Needleman, I.; Wild, SH.; Moles, DR.; Mills, EJ. (2010). Simpson, Terry C (ed.). "Treatment of periodontal disease for glycaemic control in people with diabetes". Cochrane Database Syst Rev (5): CD004714. doi:10.1002/14651858.CD004714.pub2. PMID 20464734.
  53. ^ a b c Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S (March 2010). "Exercise for the management of type 2 diabetes: a review of the evidence". Acta Diabetol. 47 (1): 15–22. doi:10.1007/s00592-009-0126-3. PMID 19495557.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  54. ^ a b Davis N, Forbes B, Wylie-Rosett J (June 2009). "Nutritional strategies in type 2 diabetes mellitus". Mt. Sinai J. Med. 76 (3): 257–68. doi:10.1002/msj.20118. PMID 19421969.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  55. ^ Thomas D, Elliott EJ (2009). Thomas, Diana (ed.). "Low glycaemic index, or low glycaemic load, diets for diabetes mellitus". Cochrane Database Syst Rev (1): CD006296. doi:10.1002/14651858.CD006296.pub2. PMID 19160276.
  56. ^ Hawthorne, K.; Robles, Y.; Cannings-John, R.; Edwards, A. G. K.; Robles, Yolanda (2008). Robles, Yolanda (ed.). "Culturally appropriate health education for Type 2 diabetes mellitus in ethnic minority groups". Cochrane Database Syst Rev (3): CD006424. doi:10.1002/14651858.CD006424.pub2. PMID 18646153. CD006424.
  57. ^ Schellenberg, ES; Dryden, DM; Vandermeer, B; Ha, C; Korownyk, C (15 October 2013). "Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis". Annals of internal medicine. 159 (8): 543–51. doi:10.7326/0003-4819-159-8-201310150-00007. PMID 24126648.
  58. ^ Boussageon, R; Supper, I; Bejan-Angoulvant, T; Kellou, N; Cucherat, M; Boissel, JP; Kassai, B; Moreau, A; Gueyffier, F; Cornu, C (2012). Groop, Leif (ed.). "Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials". PLoS medicine. 9 (4): e1001204. doi:10.1371/journal.pmed.1001204. PMC 3323508. PMID 22509138.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  59. ^ a b c Inzucchi, SE; Bergenstal, RM; Buse, JB; Diamant, M; Ferrannini, E; Nauck, M; Peters, AL; Tsapas, A; Wender, R; Matthews, DR (March 2015). "Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes". Diabetologia. 58 (3): 429–42. PMID 25583541.
  60. ^ Richter, B; Bandeira-Echtler, E; Bergerhoff, K; Clar, C; Ebrahim, SH (18 July 2007). Richter, Bernd (ed.). "Rosiglitazone for type 2 diabetes mellitus". The Cochrane database of systematic reviews (3): CD006063. doi:10.1002/14651858.CD006063.pub2. PMID 17636824.
  61. ^ Chen, X; Yang, L; Zhai, SD (December 2012). "Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies". Chinese medical journal. 125 (23): 4301–6. PMID 23217404.
  62. ^ Swinnen, SG.; Simon, AC.; Holleman, F.; Hoekstra, JB.; Devries, JH. (2011). Simon, Airin CR (ed.). "Insulin detemir versus insulin glargine for type 2 diabetes mellitus". Cochrane Database Syst Rev (7): CD006383. doi:10.1002/14651858.CD006383.pub2. PMID 21735405.
  63. ^ Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation". Health technology assessment (Winchester, England). 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
  64. ^ Lv, J; Perkovic, V; Foote, CV; Craig, ME; Craig, JC; Strippoli, GF (12 December 2012). Strippoli, Giovanni FM (ed.). "Antihypertensive agents for preventing diabetic kidney disease". The Cochrane database of systematic reviews. 12: CD004136. doi:10.1002/14651858.CD004136.pub3. PMID 23235603.
  65. ^ a b Cheng, J; Zhang, W; Zhang, X; Han, F; Li, X; He, X; Li, Q; Chen, J (May 2014). "Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis". JAMA internal medicine. 174 (5): 773–85. doi:10.1001/jamainternmed.2014.348. PMID 24687000.
  66. ^ Picot, J; Jones, J; Colquitt, JL; Gospodarevskaya, E; Loveman, E; Baxter, L; Clegg, AJ (September 2009). "The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation". Health technology assessment (Winchester, England). 13 (41): 1–190, 215–357, iii–iv. doi:10.3310/hta13410. PMID 19726018.
  67. ^ Frachetti, KJ; Goldfine, AB (April 2009). "Bariatric surgery for diabetes management". Current Opinion in Endocrinology, Diabetes and Obesity. 16 (2): 119–24. doi:10.1097/MED.0b013e32832912e7. PMID 19276974.
  68. ^ a b Schulman, AP (September–October 2009). ""Metabolic" surgery for treatment of type 2 diabetes mellitus". Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 15 (6): 624–31. doi:10.4158/EP09170.RAR. PMID 19625245. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  69. ^ Colucci, RA (January 2011). "Bariatric surgery in patients with type 2 diabetes: a viable option". Postgraduate Medicine. 123 (1): 24–33. doi:10.3810/pgm.2011.01.2242. PMID 21293081.
  70. ^ Dixon, JB (16 June 2012). "Bariatric surgery for type 2 diabetes". Lancet. 379 (9833): 2300–11. doi:10.1016/S0140-6736(12)60401-2. PMID 22683132. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  71. ^ Meetoo, D; =McGovern, P; Safadi, R (13–27 September 2007). "An epidemiological overview of diabetes across the world". British journal of nursing (Mark Allen Publishing). 16 (16): 1002–7. PMID 18026039.{{cite journal}}: CS1 maint: extra punctuation (link)
  72. ^ Abate N, Chandalia M (2001). "Ethnicity and type 2 diabetes: focus on Asian Indians". J. Diabetes Complicat. 15 (6): 320–7. doi:10.1016/S1056-8727(01)00161-1. PMID 11711326.
  73. ^ Carulli, L; Rondinella, S; Lombardini, S; Canedi, I; Loria, P; Carulli, N (November 2005). "Review article: diabetes, genetics and ethnicity". Alimentary pharmacology & therapeutics. 22 Suppl 2: 16–9. doi:10.1111/j.1365-2036.2005.02588.x. PMID 16225465.
  74. ^ Wild S, Roglic G, Green A, Sicree R, King H (May 2004). "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030". Diabetes Care. 27 (5): 1047–53. doi:10.2337/diacare.27.5.1047. PMID 15111519.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  75. ^ "Diabetes Fact sheet N°312". World Health Organization. August 2011. Retrieved 2012-01-09.
  76. ^ Ripoll, Brian C. Leutholtz, Ignacio (2011-04-25). Exercise and disease management (2nd ed.). Boca Raton: CRC Press. p. 25. ISBN 978-1-4398-2759-8.{{cite book}}: CS1 maint: multiple names: authors list (link)
  77. ^ a b c d e f g h i editor, Leonid Poretsky, (2009). Principles of diabetes mellitus (2nd ed.). New York: Springer. p. 3. ISBN 978-0-387-09840-1. {{cite book}}: |last= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
Notes

External links

This template is no longer used; please see Template:Endocrine pathology for a suitable replacement

Retrieved from "https://en.wikipedia.org/w/index.php?title=Type_2_diabetes&oldid=651153285"